Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,226 public trials 1,176 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Active, Not Recruiting

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

NCT05796089

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Extensive-stage Small-cell Lung Cancer, +8 more
Locations
  • Westmead Hospital Sydney, New South Wales, Australia
  • Blacktown Hospital Sydney, New South Wales, Australia
  • Liverpool Hospital Sydney, New South Wales, Australia
  • Royal Brisbane and Women's Hospital Brisbane, Queensland, Australia
View Trial Details
Active, Not Recruiting

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

NCT04495153

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UConn Health Farmington, Connecticut, United States
  • Yale University, Yale Cancer Center New Haven, Connecticut, United States
  • University of Chicago Chicago, Illinois, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +68 more
Locations
  • Exelixis Clinical Site #53 Gilbert, Arizona, United States
  • Exelixis Clinical Site #18 Phoenix, Arizona, United States
  • Exelixis Clinical Site #1 Duarte, California, United States
  • Exelixis Clinical Site #20 La Jolla, California, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT05864144

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Cancer, +101 more
Locations
  • UCLA Hematology/Oncology Los Angeles, California, United States
  • University of Colorado Cancer Center - Anschutz Medical Aurora, Colorado, United States
  • Norton Healthcare Louisville, Kentucky, United States
  • Henry Ford Cancer Detroit, Michigan, United States
View Trial Details
Active, Not Recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NCT03620669

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Kantonsspital Aarau Aarau, Switzerland
  • Kantonsspital Baden Baden, Switzerland
  • Universitaetsspital Basel Basel, Switzerland
  • IOSI Ospedale Regionale di Bellinzona e Valli Bellinzona, Switzerland
View Trial Details
Active, Not Recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03893955

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +17 more
Locations
  • Highlands Oncology Group, PA /ID# 218863 Springdale, Arkansas, United States
  • St Jude Hospital dba St Joseph /ID# 211130 Santa Rosa, California, United States
  • Yale University School of Medicine /ID# 210678 New Haven, Connecticut, United States
  • Moffitt Cancer Center /ID# 215037 Tampa, Florida, United States
View all 26 locations
View Trial Details
Active, Not Recruiting

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06091943

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
View all 15 locations
View Trial Details
Active, Not Recruiting

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

NCT02273375

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • USC Norris/Comprehensive Cancer Centre Los Angeles, California, United States
  • National Jewish Health Denver, Colorado, United States
  • University of Florida Gainesville, Florida, United States
View all 271 locations
View Trial Details

Related conditions